Equine Mesenchymal Stem Cell Therapy for Insect-Bite Hypersensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for insect-bite hypersensitivity (IBH) in horses are inadequate, with glucocorticoids causing severe adverse effects and other therapies offering limited efficacy, leading to significant animal suffering and reduced commercial value.
Innovation Solution
The use of mesenchymal stem cells (MSCs), particularly derived from peripheral blood, administered intravenously, to modulate the immune response and reduce IBH symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If glucocorticoids are used to treat IBH, then inflammatory response is suppressed, but severe adverse effects occur
Solution Approach 1:
The patent uses mesenchymal stem cells as an intermediary substance to mediate the treatment of IBH. These cells modulate the immune response through paracrine mechanisms and immunomodulation, providing anti-inflammatory effects without the severe adverse effects of glucocorticoids. The stem cells act as a biological mediator that restores immune balance rather than simply suppressing inflammation.
Solution Approach 2:
The patent changes the treatment parameter from pharmacological suppression (glucocorticoids) to cellular therapy (mesenchymal stem cells). This parameter change shifts the mechanism from direct anti-inflammatory drug action to immunomodulation through stem cell differentiation and cytokine secretion, achieving therapeutic effect with improved safety profile.
2Shape
If topical treatments are applied to alleviate clinical signs, then skin elasticity improves, but pruritus and disease progression are not influenced
Solution Approach 1:
The patent employs autologous mesenchymal stem cells that are harvested from the patient's own bone marrow or adipose tissue. These cells naturally differentiate and secrete trophic factors that promote skin regeneration and modulate immune responses. The self-service principle is embodied in using the patient's own cells to treat their condition, eliminating rejection risks and achieving both structural and functional improvement.
Solution Approach 2:
The treatment combines multiple therapeutic mechanisms in one intervention: immunomodulation through cytokine secretion, tissue regeneration through differentiation into skin cells, and anti-fibrotic effects. This composite approach addresses both the structural skin damage and the functional pruritus simultaneously, unlike single-mechanism topical treatments.
3Object-affected harmful factors
If allergen-specific immunotherapy is administered, then immune response is modulated, but efficacy remains limited
Solution Approach 1:
Instead of trying to desensitize the immune system to allergens through gradual exposure (conventional ASIT), the patent inverts the approach by directly modulating the immune system's response capacity using mesenchymal stem cells. The treatment shifts from antigen-specific desensitization to broad immunomodulation, restoring immune balance and reducing hypersensitivity through cellular therapy rather than continued antigen exposure.
Data Source
AI summary
The current invention relates to mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising an effective amount of MSCs for use in the treatment of insect-bite hypersensitivity (IBH) in equines.